PL2262476T3 - Dostarczanie leku do przedniego i tylnego odcinka oka z użyciem kropli do oczu - Google Patents

Dostarczanie leku do przedniego i tylnego odcinka oka z użyciem kropli do oczu

Info

Publication number
PL2262476T3
PL2262476T3 PL08737584T PL08737584T PL2262476T3 PL 2262476 T3 PL2262476 T3 PL 2262476T3 PL 08737584 T PL08737584 T PL 08737584T PL 08737584 T PL08737584 T PL 08737584T PL 2262476 T3 PL2262476 T3 PL 2262476T3
Authority
PL
Poland
Prior art keywords
eye
anterior
drug delivery
posterior segments
eye drops
Prior art date
Application number
PL08737584T
Other languages
English (en)
Inventor
Raouf Rekik
Original Assignee
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raouf Rekik filed Critical Raouf Rekik
Publication of PL2262476T3 publication Critical patent/PL2262476T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08737584T 2008-03-11 2008-05-05 Dostarczanie leku do przedniego i tylnego odcinka oka z użyciem kropli do oczu PL2262476T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TNP2008000110A TNSN08110A1 (en) 2008-03-11 2008-03-11 Drug delivery to the anterior and posterior segment of the eye from drops
PCT/IB2008/001102 WO2009112878A1 (en) 2008-03-11 2008-05-05 Drug delivery to the anterior and posterior segments of the eye using eye drops.
EP08737584.6A EP2262476B1 (en) 2008-03-11 2008-05-05 Drug delivery to the anterior and posterior segments of the eye using eye drops.

Publications (1)

Publication Number Publication Date
PL2262476T3 true PL2262476T3 (pl) 2018-12-31

Family

ID=59846201

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08737584T PL2262476T3 (pl) 2008-03-11 2008-05-05 Dostarczanie leku do przedniego i tylnego odcinka oka z użyciem kropli do oczu

Country Status (7)

Country Link
US (2) US20110104155A1 (pl)
EP (1) EP2262476B1 (pl)
CA (1) CA2718161C (pl)
ES (1) ES2686173T3 (pl)
PL (1) PL2262476T3 (pl)
TN (1) TNSN08110A1 (pl)
WO (1) WO2009112878A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
AR084194A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Derivados de arilsulfonamida para la prevencion o el tratamiento de trastornos oftalmologicos especificos
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
CA3049795A1 (en) 2011-09-20 2013-03-28 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2013063269A2 (en) * 2011-10-25 2013-05-02 Case Western Reserve University Compounds and methods of treating ocular disorders
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP7037360B2 (ja) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド 拡張可能な薬物送達デバイス
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
WO2018054489A1 (en) * 2016-09-23 2018-03-29 Hallboeoek Finn Pharmacological treatment of myopia
CA3061900A1 (en) * 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agriculturaand Mechanical College Compositions and methods for treating ocular pathologies
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
WO2022242766A1 (zh) * 2021-05-21 2022-11-24 成都文鼎科技发展有限公司 一种调节神经病变的方法
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5212168A (en) * 1991-02-26 1993-05-18 New England Medical Center Hospital, Inc. Method of and solution for treating glaucoma
SG84487A1 (en) * 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
WO2000076499A2 (fr) * 1999-06-16 2000-12-21 Rekik, Elyes, Ben, Mohamed, Raouf Medicaments ophtalmologiques neuro-et retino-protecteurs
JP2004504389A (ja) * 2000-07-13 2004-02-12 アルテオン　インコーポレーテッド シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療
CA2434485A1 (en) * 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050239872A1 (en) * 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
US7785578B2 (en) * 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
US20040213782A1 (en) * 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor

Also Published As

Publication number Publication date
US20110104155A1 (en) 2011-05-05
TNSN08110A1 (en) 2009-07-14
EP2262476B1 (en) 2018-06-06
CA2718161C (en) 2016-08-16
EP2262476A1 (en) 2010-12-22
ES2686173T3 (es) 2018-10-16
CA2718161A1 (en) 2009-09-17
US20140011809A1 (en) 2014-01-09
WO2009112878A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
SG2014007389A (en) Posterior segment drug delivery
ZA201003911B (en) Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
EP2255788A4 (en) LIPOSOM FOR DELIVERY TO A BACK SEGMENT OF THE EYE AND PHARMACEUTICAL COMPOSITION FOR DISEASES IN THE BACK EYE SEGMENT
EP2600920A4 (en) Subconjunctival implant for posterior segment drug delivery
ZA201301155B (en) Ophthalmic drug delivery
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
PL2493459T3 (pl) Urządzenia do doocznego podawania leku
ZA201208069B (en) Methods and devices for drug delivery to ocular tissue using microneedle
IL216972A0 (en) Implantable drug delivery devices and methods of making the same
IL215205A0 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
ZA201201712B (en) Novel pharmaceutical formulations against drug misuse
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
WO2013103919A3 (en) Compositions and methods for treating metabolic disorders
LT2739615T (lt) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanonai ir jų panaudojimas kaip vaisto
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
PL2318062T3 (pl) Nowe biomateriały, ich przygotowywanie przez elektrowirowanie i stosowanie w dziedzinach biomedycznych i chirurgicznych
WO2013171764A3 (en) Ophthalmic formulations
EP2488210A4 (en) METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
IL227352A0 (en) A system for ocular administration of a drug
EP2328511A4 (en) ACTIVE RELEASE IMPLANTS
EP2408511A4 (en) APPARATUS FOR DELIVERY OF SOLID MEDICAMENTS, PREPARATIONS AND METHODS OF USE
IL208751A0 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
HUE037689T2 (hu) Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra